NRSN
NASD Neurosense Therapeutics Ltd.$3.94 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.94, $0.07 below the day’s high of $4.01
- YTD change
- -74.41%
- vs 20-day SMA
- -41.97%
- vs 200-day SMA
- -72.63%
Price ranges
Price & Performance
+3.17 (+416.40%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 97.6% away from all-time highs of $163.60
- NRSN is down 74% since the beginning of the year
- NRSN is down 84% over the past 12 months
- NRSN is down 52% over the past 1 month
- 3% of all NRSN investors are betting against NRSN
NRSN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +214.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.33
- Last 5 days
- -46.82%
- vs 8-day SMA
- -33.43%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.